Fig. 3.

Pharmacokinetic analysis of Schedule A patients. a Serum erlotinib levels were determined for these patients at day 6 (erlotinib alone, left panel) and at day 14 (erlotinib + rosuvastatin treatments) every 2 h following drug administration for 24 h. b For the 5 evaluable patients (14–18), area under the curve (AUC) values showed no statistical difference between the two treatments with respect to serum erlotinib exposure. P value determined by T test. c Serum rosuvastatin levels were determined for these patients at day 14 (erlotinib +1 mg/mg/day rosuvastatin treatments) every 2 h following drug administration for 24 h